Genentech and Human Longevity Inc. announce multi-year agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GENENTECH and Human Longevity Inc. signed a multi-year agreement to conduct whole genome sequencing of tens of thousands of de-identified samples provided by Genentech, a member of the Roche Group.

HLI will sequence genomes to 30x coverage and analyze the data. Financial details of the agreement were not disclosed.

HLI is building a comprehensive integrated human genotype and phenotype database, the HLI Knowledgebase, using Illumina’s HiSeq X Ten and HiSeq 2500 sequencing machines and Pac Bio RS II instruments.

YOU MAY BE INTERESTED IN

New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login